Examination of the potential long-lasting protective effect of ICRF-187 against anthracycline-induced chronic cardiomyopathy.
Herman
E H
EH
Division of Drug Research and Testing, Food and Drug, Administration, Washington, D.C. 20204.
Ferrans
V J
VJ
D000818:Animals; D009202:Cardiomyopathies / Q000139:chemically induced / Q000473:pathology / Q000517:prevention & control*; D002908:Chronic Disease; D003630:Daunorubicin / Q000009:adverse effects*; D008297:Male; D009206:Myocardium / Q000473:pathology; D009210:Myofibrils / Q000187:drug effects / Q000473:pathology; D011817:Rabbits; D011929:Razoxane / Q000627:therapeutic use*; D013997:Time Factors; D014617:Vacuoles / Q000187:drug effects / Q000473:pathology
D011929:Razoxane; D003630:Daunorubicin